Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Familial Cancer
Published in: Familial Cancer 1/2021

01-01-2021 | Editorial Comment

The CAPP II trial of aspirin in Lynch syndrome/HNPCC: is it time for everyone to be treated?

Author: Patrick M. Lynch

Published in: Familial Cancer | Issue 1/2021

Login to get access

Excerpt

In a recent issue of the Lancet, John Burn and collaborators from the CAPP II consortium, published long-term outcomes data from that trial [1]. This comprised up to 20 years of follow-up of patients, mainly a subset from the UK and Finland, who had received aspirin at a dose of 600 mg/day for an average of 25 months, or placebo. …
Literature
1.
Burn J, Sheth H, Elliott F, Reed L, Macrae F, Mecklin JP et al (2020) Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lancet 395(10240):1855–1863CrossRef
2.
Burn J, Bishop DT, Mecklin JP, Macrae F, Moslein G, Olschwang S et al (2008) Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med 359(24):2567–2578CrossRef
3.
Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S et al (2011) Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378(9809):2081–2087CrossRef
4.
Yurgelun MB, Chan AT (2020) Aspirin for Lynch syndrome: a legacy of prevention. Lancet 395(10240):1817–1818CrossRef
5.
Reyes-Uribe L, Wu W, Gelincik O, Bommi PV, Francisco-Cruz A, Solis LM et al (2020) Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa. Gut 69(10):1–12
6.
Pommergaard HC, Burcharth J, Rosenberg J, Raskov H (2016) Aspirin, calcitriol, and calcium do not prevent adenoma recurrence in a randomized controlled trial. Gastroenterology. 150(1):114-122.e4CrossRef
7.
McNeil JJ, Wolfe R, Woods RL, Tonkin AM, Donnan GA, Nelson MR et al (2018) Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med 379(16):1509–1518CrossRef
8.
McNeil JJ, Nelson MR, Woods RL, Lockery JE, Wolfe R, Reid CM et al (2018) Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med 379(16):1519–1528CrossRef
9.
Engel C, Vasen HF, Seppala T, Aretz S, Bigirwamungu-Bargeman M, de Boer SY et al (2018) No difference in colorectal cancer incidence or stage at detection by colonoscopy among 3 countries with different lynch syndrome surveillance policies. Gastroenterology. 155(5):1400-1409.e2CrossRef
Metadata
Title
The CAPP II trial of aspirin in Lynch syndrome/HNPCC: is it time for everyone to be treated?
Author
Patrick M. Lynch
Publication date
01-01-2021
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 1/2021
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-020-00215-z

Other articles of this Issue 1/2021

Familial Cancer 1/2021 Go to the issue

Short Communication

Multiple primary cancers (renal papillary, lymphoma and teratoma) and hepatic cysts in association with a pathogenic germline mutation in the MET gene

Short Communication

Two cases of somatic STK11 mosaicism in Danish patients with Peutz–Jeghers syndrome

Review

Prospective observational data informs understanding and future management of Lynch syndrome: insights from the Prospective Lynch Syndrome Database (PLSD)

Original Article

Small fraction of testicular cancer cases may be causatively related to CHEK2 inactivating germ-line mutations: evidence for somatic loss of the remaining CHEK2 allele in the tumor tissue

Original Article

Germline variants discovered in lymphoma patients undergoing tumor profiling: a case series

Original Article

Low accuracy of self-reported family history of melanoma in high-risk patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits